BeyondSpring is trading at $0.78 (+9.98%), with no fresh August 25 company announcement identified.
- The latest company release, published August 15, summarized August 14 results and clinical updates, including long-term plinabulin data.
- Broader futures are modestly higher, but the Nasdaq’s +0.46% gain does not clearly explain this isolated move.
- The catalyst remains unconfirmed pending additional filings or news.